Dennis M. Lanfear
President & CEO at Coherus Oncology Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Coherus Oncology Inc., 3 years.
Coherus Oncology Inc.
Director · President & CEO
Chief executive roles
Coherus Oncology Inc.
· President & CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 20, 2024 | Coherus Oncology Inc. | Shares withheld for tax | −11,218 | $2.44 | $27,372 |
| Jan 4, 2024 | Coherus Oncology Inc. | Shares withheld for tax | −11,781 | $2.92 | $34,401 |
| Nov 22, 2023 | Coherus Oncology Inc. | Option exercise | +41,000 | $1.42 | $58,220 |
| Nov 22, 2023 | Coherus Oncology Inc. | Option exercise | +258,940 | $1.42 | $367,695 |
| Nov 22, 2023 | Coherus Oncology Inc. | Open-market sale | −223,100 | $2.02 | $450,662 |
| Jan 20, 2023 | Coherus Oncology Inc. | Grant or award | +86,250 | — | — |
| Jan 4, 2023 | Coherus Oncology Inc. | Shares withheld for tax | −10,905 | $9.87 | $107,632 |
| Dec 30, 2022 | Coherus Oncology Inc. | Gift | −4,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.